Cancer of the head and neck region in solid organ transplant recipients

Rabinovics, Naomi; Mizrachi, Aviram; Hadar, Tuvia; Ad‐El, Dean; Feinmesser, Raphael; Guttman, Dan; Shpitzer, Thomas; Bachar, Gideon

doi:10.1002/hed.23283

Cited by 45 publications

(54 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a recent study, Nelissen and co-workers reported the overall five-year survival for head and neck tumours in a Belgian SOT patient cohort to be slightly more than 50% [9]. In an Israeli cohort the five-year overall survival rate was 74% for head and neck malignancies [13]. In a nationwide study of all SOT patients transplanted in Sweden between 1970 and 1997 Adami and collaborators [27] report standard incidence ratios for oral and lip cancer in accordance with our findings.…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Oral and lip cancer in solid organ transplant patients – A cohort study from a Swedish Transplant Centre

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

“…Also in the head-neck region there is an increase in cancer incidence [9]. Head and neck cancers have been reported to constitute 4-15% of all malignant tumours after transplantation [10][11][12][13]. An increased incidence of lip cancer has also been reported [14,15].…”

Section: Introductionmentioning

confidence: 92%

Oral and lip cancer in solid organ transplant patients – A cohort study from a Swedish Transplant Centre

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In a population‐based nested case‐control study performed in the Swedish organ transplantation cohort, AZA was strongly associated with increased post‐transplant cutaneous SCC risk . Furthermore, a separate study recently reported that patients treated with AZA displayed significantly more aggressive head and neck tumors than patients receiving other immunosuppressive drugs . A large, multicenter, double‐blind and randomized controlled trial in which cardiac transplant patients received either AZA or MMF (alongside cyclosporine and corticosteroids) at the time of transplant showed no difference between these drugs in terms of NMSC incidence, although AZA‐treatment was associated with a significantly poorer rate of survival or an increased requirement for a second transplant when compared with MMF‐treatment .…”

Section: Nmsc Risk Is Associated With Immunosuppression Regimementioning

confidence: 99%

Does the nature of residual immune function explain the differential risk of non‐melanoma skin cancer development in immunosuppressed organ transplant recipients?

Jung

Overgaard

Burke

et al. 2015

Intl Journal of Cancer

View full text Add to dashboard Cite

Patients receiving immunosuppression to prevent organ transplant rejection are at a greatly increased risk of developing nonmelanoma skin cancer. In recent years a correlation has been identified between the class of immunosuppressant that these patients receive and their subsequent cancer risk; in particular, patients switched from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors not only displayed a dramatic reduction in new tumor formation but also in some cases a regression of their existing lesions. Studies of cancer models in mice and cell lines in the laboratory have attributed these discrepancies in cancer risk to the ability of immunosuppressants such as mTOR inhibitors to elicit direct anticancer effects, including suppressing angiogenesis and increasing autophagy‐mediated DNA repair. Recent evidence from the immunological literature however, suggests a significant alternative contribution of mTOR inhibitors; namely the promotion of memory T‐cell function. Recent advances in understanding memory T‐cell establishment and the demonstration of their critical role in long‐term immunity make it timely to review the available evidence as to whether the improved nonmelanoma skin cancer outcome shown by patients switched to mTOR inhibitor treatment regimens may be associated with the retainment of memory T‐cell function.

show abstract

“…This tumor burden increases the disease severity, deep tissue spread, and perineural and lymphatic invasion and recurrence, owing to an infectious cause with higher level of human papillomavirus DNA in squamous cell carcinoma. 34,35 Also, solar keratosis and older age are more common in patients with squamous cell carcinoma versus those without the disease. 33 After carcinoma, another common skin cancer is melanoma, which occurs mainly in patients with fair complexion, light hair and eyes, and a tendency to freckle.…”

Section: Malignancies After Heart Transplantmentioning

confidence: 99%

Untitled

Lateef

Basit²,

Abbasi³

et al. 2016

Exp Clin Transplant

View full text Add to dashboard Cite

Along with graft vasculopathy, malignancies comprise a major complication after heart transplant, with a rate of occurrence of 39.1% in 10 years. Skin cancers and posttransplant lymphoproliferative disorder are more common in adults, whereas lymphoma is more often shown in children. A major cause of malignancies after heart transplant is the use of increased doses of prophylactics needed during immunosuppressive therapy. Data, however, are scarce regarding the association between a particular immunosuppressive drug and a posttransplant malignancy. Compared with the general population, recipients have a higher incidence of malignancies after heart transplant, with an early onset and more aggressive disease. Solid tumors known to occur in heart transplant recipients include lung cancer, bladder and prostate carcinoma, adenocarcinoma of the oral cavity, stomach cancer, and bowel cancer, although the incidence is rare. The risk factors for development of a malignancy after heart transplant are the same as for the nontransplant population.

show abstract

Cancer of the head and neck region in solid organ transplant recipients

Abstract: Organ transplantation recipients are at a higher risk to develop head and neck cancer with an aggressive behavior characterized by multiple recurrences and decreased survival.

Cited by 45 publications

References 25 publications

Oral and lip cancer in solid organ transplant patients – A cohort study from a Swedish Transplant Centre

Oral and lip cancer in solid organ transplant patients – A cohort study from a Swedish Transplant Centre

Does the nature of residual immune function explain the differential risk of non‐melanoma skin cancer development in immunosuppressed organ transplant recipients?

Untitled

Contact Info

Product

Resources

About